Trial Profile
A Randomized, Double-Blind, Parallel-Group Clinical Study to Compare Pharmacokinetics, Safety and Tolerability of LBAL 40 mg With Humira® 40 mg After a Single Subcutaneous Administration in Healthy Male Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Jul 2017
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors LG Life Sciences
- 12 Jun 2015 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov record.
- 05 Aug 2014 New trial record